source
- Georgiamune to ship preclinical solid tumor drug to Menarini in deal up to $1.1 billionGeorgiamune, a small biotech based in Maryland, announced that it will supply its preclinical solid tumor candidate to Menarini, a family‑owned pharmaceutical company in Italy. The agreement is st…
- Investors Re-evaluate Kidney Disease as New Cell and Gene Therapy Strategies EmergeIn a recent episode of BioSpace's Denatured podcast, the CEOs of ProKidney and Nephrogen discussed why kidney disease has long been a difficult indication for cell and gene-based medicines. The co…